Pacira BioSciences (PCRX) Expected to Announce Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to be posting its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Pacira BioSciences to post earnings of $0.66 per share and revenue of $182.8560 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm had revenue of $181.10 million during the quarter, compared to analysts’ expectations of $183.11 million. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.96 EPS. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX opened at $22.44 on Wednesday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -8.07 and a beta of 0.40. Pacira BioSciences has a 1-year low of $16.00 and a 1-year high of $27.64. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average price of $24.54 and a two-hundred day moving average price of $24.52.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the transaction, the director owned 11,393 shares of the company’s stock, valued at approximately $269,672.31. This represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds have recently modified their holdings of PCRX. Strs Ohio acquired a new stake in shares of Pacira BioSciences during the first quarter worth about $75,000. State of Wyoming bought a new stake in Pacira BioSciences during the 2nd quarter worth approximately $102,000. Tower Research Capital LLC TRC increased its stake in Pacira BioSciences by 227.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,624 shares of the company’s stock worth $111,000 after purchasing an additional 3,213 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Pacira BioSciences during the 2nd quarter worth approximately $310,000. Finally, Sei Investments Co. increased its stake in Pacira BioSciences by 35.3% during the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock worth $606,000 after purchasing an additional 6,609 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Pacira BioSciences in a report on Wednesday, October 8th. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, Truist Financial raised Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Friday, July 25th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $33.40.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.